Katie Ellias is the Managing Director of T1D Fund since 2018, where she has led a number of investments in companies developing T1D-oriented therapies. She currently serves as a director on the board of SAB Biotherapeutics (NASDAQ: SABS), represents the T1D Fund as a director of DiogenX, and Veralox Therapeutics, and serves on the board of Fund companies Nipuna, Therapeutics, Cour Therapeutics, Seraxis, i2O Therapeutics, and Biolinq. Ms. Ellias joined the T1D Fund from Endeavour Vision, a Geneva-based growth stage venture fund. She was previously Principal at Sofinnova Partners, Paris, a leading early-stage life sciences fund. Ms. Ellias has also held commercial and business development roles with Medtronic and started her career at McKinsey & Company. Katie holds an M.B.A. in Healthcare Management from the Wharton School at the University of Pennsylvania and a B.A. in International Relations and Political Science from Yale University.